Prostate Cancer Treatment by Stage: Complete Guide
- How is prostate cancer staged?
- Low-risk (Stage I) – active surveillance is standard
- Favorable intermediate-risk (Stage II) – options
- Unfavorable intermediate-risk (Stage II) – treatment
- High-risk (Stage III) – surgery or radiation + ADT
- Very high-risk (Stage III) – multimodal therapy
- Metastatic (Stage IV) – ADT + systemic therapy
- Treatment algorithm – visual guide
- Interactive FAQ – 9 questions about treatment by stage
How is prostate cancer staged?
Prostate cancer staging combines three factors to determine risk groups:
- T stage (Tumor): How far has the cancer spread within and around the prostate? (T1-T4)
- Gleason score / Grade Group: How aggressive are the cancer cells? (Grade Group 1-5)
- PSA level: Prostate-specific antigen (ng/mL)
These factors are combined into risk groups (low, intermediate, high, very high, metastatic) that guide treatment decisions.
Low-risk (Stage I) – active surveillance is standard
Definition: T1-T2a, Gleason 6 (Grade Group 1), PSA <10 ng/mL
Treatment options:
- Active surveillance (standard of care): Monitor with PSA every 6 months, DRE annually, MRI every 1-3 years, repeat biopsy at 12-18 months then every 2-3 years. Treatment only if cancer progresses.
- Surgery (radical prostatectomy): Overtreatment for most – not recommended unless patient preference.
- Radiation therapy (IMRT or brachytherapy): Overtreatment for most – not recommended unless patient preference.
10-year prostate cancer-specific survival:
- >99% – most men will not die from low-risk prostate cancer
Favorable intermediate-risk (Stage II) – options
Definition: Gleason 3+4=7 (Grade Group 2) AND PSA <10 ng/mL AND T1-T2c (no high-risk features)
Treatment options:
- Active surveillance (select patients): For men with low volume of pattern 4 (<10-20%), negative MRI. Discuss with urologist.
- Surgery (radical prostatectomy): Curative, provides definitive staging, avoids ADT.
- Radiation therapy (IMRT or brachytherapy): Curative. Short-term ADT (4-6 months) may be added.
10-year prostate cancer-specific survival:
- >95%
Unfavorable intermediate-risk (Stage II) – treatment
Definition: Gleason 4+3=7 (Grade Group 3) OR PSA 10-20 ng/mL OR T2b-T2c OR multiple intermediate-risk factors
Treatment options:
- Surgery (radical prostatectomy): Curative. May need lymph node dissection.
- Radiation therapy (IMRT or brachytherapy) + short-term ADT (4-6 months): ADT improves outcomes.
10-year prostate cancer-specific survival:
- 90-95%
High-risk (Stage III) – surgery or radiation + ADT
Definition: Gleason 8 (Grade Group 4) OR PSA >20 ng/mL OR T3a
Treatment options:
- Surgery (radical prostatectomy) + lymph node dissection: Curative, but higher risk of positive margins and recurrence.
- Radiation therapy (IMRT) + long-term ADT (18-36 months): ADT is essential for high-risk cancer.
- Radiation + brachytherapy boost + ADT: For select patients.
10-year prostate cancer-specific survival:
- 80-90%
Very high-risk (Stage III) – multimodal therapy
Definition: Gleason 9-10 (Grade Group 5) OR T3b-T4 OR ≥2 high-risk features
Treatment options:
- Surgery (radical prostatectomy) + lymph node dissection: For select patients, but high risk of positive margins and recurrence. Often requires adjuvant radiation.
- Radiation therapy (IMRT) + long-term ADT (24-36 months) + brachytherapy boost: Intensified therapy improves outcomes.
- ADT + abiraterone + radiation: For very high-risk localized disease (STAMPEDE trial).
10-year prostate cancer-specific survival:
- 70-80%
Metastatic (Stage IV) – ADT + systemic therapy
Definition: Any T, any N, M1 (distant metastases – bone, lymph nodes, viscera)
Treatment options (mHSPC – hormone-sensitive):
- ADT + docetaxel (chemotherapy): For high-volume disease – improves survival by 13-17 months
- ADT + abiraterone (Zytiga): For all mHSPC – improves survival
- ADT + enzalutamide (Xtandi): For all mHSPC – improves survival
- ADT + apalutamide (Erleada): For all mHSPC – improves survival
- ADT + darolutamide (Nubeqa): For mHSPC – improves survival
Treatment options (mCRPC – castration-resistant):
- First-line: Abiraterone, enzalutamide, or docetaxel
- Second-line: Cabazitaxel, radium-223 (bone-only), PARP inhibitors (if HRR mutation)
- Third-line: Lu-177-PSMA (Pluvicto)
5-year survival:
- 30-50% (improving with new therapies)
Treatment algorithm – visual guide
Localized prostate cancer (T1-T2, N0, M0):
- Low-risk: Active surveillance (preferred) → Surgery or radiation if patient preference
- Favorable intermediate-risk: Active surveillance (select) OR surgery OR radiation
- Unfavorable intermediate-risk: Surgery OR radiation + short-term ADT (4-6 months)
- High-risk: Surgery + LND OR radiation + long-term ADT (18-36 months)
- Very high-risk: Radiation + ADT + abiraterone OR surgery + adjuvant radiation
Metastatic prostate cancer (M1):
- mHSPC (hormone-sensitive): ADT + abiraterone/enzalutamide/apalutamide OR ADT + docetaxel (high-volume)
- mCRPC (castration-resistant): Sequential therapy: abiraterone/enzalutamide → docetaxel → cabazitaxel → Lu-177-PSMA/PARP inhibitors
Interactive FAQ – Prostate cancer treatment by stage
No – active surveillance is the standard of care. Immediate treatment causes side effects without survival benefit.
Favorable: Gleason 3+4=7 with low volume of pattern 4. Unfavorable: Gleason 4+3=7 or PSA 10-20 or T2b-T2c. Unfavorable requires treatment.
With radiation, yes – long-term ADT (18-36 months) improves survival. With surgery, ADT is not routine but may be used if recurrence.
Yes – many men with high-risk localized (Stage III) prostate cancer are cured with surgery or radiation + ADT.
ADT plus a second agent (abiraterone, enzalutamide, apalutamide, or docetaxel). Choice depends on disease volume and prior treatments.
Median survival is now 5-7+ years. Some men live 10+ years with low-volume disease and good response to treatment.
For select patients with low volume of pattern 4 (<10-20%) and negative MRI, active surveillance may be an option. Discuss with your urologist.
ADT is used for intermediate/high-risk localized cancer (with radiation), metastatic cancer (with other agents), and recurrent cancer.
Yes – but there is a higher risk of positive margins and recurrence. Adjuvant radiation may be needed.
Disclaimer: This information is for educational purposes. Treatment decisions should be individualised based on patient age, comorbidities, and preferences. Consult a urologist at Vivekananda Hospital.